BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19800674)

  • 1. The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.
    Vernooij F; Witteveen PO; Verweij E; van der Graaf Y; Heintz AP
    Gynecol Oncol; 2009 Dec; 115(3):343-8. PubMed ID: 19800674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
    Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
    J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
    Meyerhardt JA; Tepper JE; Niedzwiecki D; Hollis DR; Schrag D; Ayanian JZ; O'Connell MJ; Weeks JC; Mayer RJ; Willett CG; MacDonald JS; Benson AB; Fuchs CS
    J Clin Oncol; 2004 Jan; 22(1):166-74. PubMed ID: 14701779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands.
    Vernooij F; Heintz AP; Coebergh JW; Massuger LF; Witteveen PO; van der Graaf Y
    Gynecol Oncol; 2009 Mar; 112(3):455-61. PubMed ID: 19136148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
    Bristow RE; Palis BE; Chi DS; Cliby WA
    Gynecol Oncol; 2010 Sep; 118(3):262-7. PubMed ID: 20573392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer.
    Paulsen T; Kaern J; Kjaerheim K; Haldorsen T; Tropé C
    Gynecol Oncol; 2006 Sep; 102(3):447-52. PubMed ID: 16516277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
    Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
    Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Moore KN; Reid MS; Fong DN; Myers TK; Landrum LM; Moxley KM; Walker JL; McMeekin DS; Mannel RS
    Gynecol Oncol; 2008 Aug; 110(2):133-9. PubMed ID: 18495221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care.
    von Gruenigen V; Daly B; Gibbons H; Hutchins J; Green A
    Cancer; 2008 May; 112(10):2221-7. PubMed ID: 18348300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients.
    Engel J; Kerr J; Eckel R; Günther B; Heiss M; Heitland W; Siewert JR; Jauch KW; Hölzel D
    Eur J Surg Oncol; 2005 Jun; 31(5):512-20. PubMed ID: 15878259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.
    Levine D; Park K; Juretzka M; Esch J; Hensley M; Aghajanian C; Lewin S; Konner J; Derosa F; Spriggs D; Iasonos A; Sabbatini P
    Cancer; 2007 Dec; 110(11):2448-56. PubMed ID: 17918264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.